0 Replies
Oct 11, 2012 (Marketwire via COMTEX) --Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading RNAi-based drug discovery and development company, today reported financial results for the fiscal year ended December 31, 2011, and provided an update on recent corporate accomplishments and strategic direction.
"The past nine months have been an extremely... Contine Reading & Discuss→
0 Replies
Aug 22, 2012 (Marketwire via COMTEX) --Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today provided an update on its operations. The Company continues to seek adequate funding to implement its business plan and has accomplished the following in order to generate revenue, reduce... Contine Reading & Discuss→
0 Replies
Aug 03, 2012 (Marketwire via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, announced today that it has entered into a licensing agreement with Novartis for Marina Biotech's Conformationally Restricted Nucleotide (CRN) technology for the development of both single- and double-stranded oligonucleotide therapeutics. Marina... Contine Reading & Discuss→
0 Replies
Continues to Seek Substantial Funding and Strategic Opportunities
BOTHELL, WA, Jun 01, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today announced that it does
not currently have adequate funding to continue implementing its
business plan. To conserve available cash,... Contine Reading & Discuss→
0 Replies
CINCINNATI, OH and HANNOVER, GERMANY and BOTHELL, WA, May 21, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, and Girindus Group today
announced that they have entered into a strategic alliance where
Girindus will have exclusive rights to develop, supply... Contine Reading & Discuss→
0 Replies
Expands Patent Protection for SMARTICLES(R) and DiLA2(TM) Delivery Platforms
BOTHELL, WA, May 10, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today announced that the U.S.
Patent and Trademark Office (USPTO) has issued a Notice of Allowance
for patent applications... Contine Reading & Discuss→
0 Replies
BOTHELL, WA, May 08, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA) announced today that it has
entered into an exclusive licensing agreement with Monsanto Company
for Marina Biotech's delivery and chemistry technologies. Terms of
the agreement were not disclosed.
"We are pleased to enter into this agreement with... Contine Reading & Discuss→
0 Replies
Cambridge Biolabs Will Still Maintain a License for Certain Veterinary Applications
BOTHELL, WA, Apr 19, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today announced that it has
regained intellectual property rights to its transkingdom RNAi
(tkRNAi) drug discovery platform... Contine Reading & Discuss→
0 Replies
BOTHELL, WA, Apr 03, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today announced the
completion of dosing for Cohort 2 in the Dose Escalation Phase of its
START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial
Adenomatous Polyposis)... Contine Reading & Discuss→
